Crystal's Coder Hub🧬 ICD-10-CM H35.3211 — Exudative Age-Related Macular Degeneration, Right Eye, With Active Choroidal Neovascularization
Billable Code Confirmed
ICD-10-CM H35.3211 is a valid, billable 7-character ICD-10-CM code for FY2026. The 6th character (“1”) specifies the right eye, and the 7th character (“1”) dictates the presence of active choroidal neovascularization. No additional characters are required.
Non-Billable Parent Codes — Never Submit These
- ❌
H35.32— 5-character header — Lacks eye laterality and neovascularization status.- ❌
H35.321— 6-character header — Lacks specification of active vs. inactive choroidal neovascularization.Always submit H35.3211 (all 7 characters) when right eye exudative AMD is documented with active vascular leakage or neovascular growth.
Clinical Context: Active vs. Inactive Neovascularization
ICD-10-CM H35.3211 captures the active phase of wet AMD. The 7th character “1” indicates that abnormal blood vessels (choroidal neovascularization, or CNV) are actively growing and leaking fluid, lipids, or blood into the subretinal space. This distinction is the primary driver for medical necessity for costly anti-VEGF intravitreal injections. If the CNV is inactive or scarred, different 7th characters apply, and active treatment is typically paused.1
Code Classification
ICD-10-CM Diagnosis Code — wRVU, assistant payable, and global period fields are not applicable to diagnosis codes. See the Commonly Associated CPT Codes and ICD-10-PCS Crosswalk sections below for procedural billing pairings.
🔍 Code Description
ICD-10-CM H35.3211 classifies exudative age-related macular degeneration, right eye, with active choroidal neovascularization. It indicates a severe, sight-threatening ocular condition in the right eye where abnormal, fragile blood vessels from the choroid penetrate the Bruch’s membrane and leak fluid or blood into the macula, causing rapid distortion and loss of central vision.
Pathophysiologically, “exudative” (wet) AMD is triggered by the over-expression of Vascular Endothelial Growth Factor (VEGF) secondary to retinal hypoxia or degenerative changes. The resulting active choroidal neovascular membranes (CNVM) disrupt the retinal architecture. If the leakage is not arrested promptly via anti-VEGF therapy, irreversible fibrovascular scarring and permanent central blindness will ensue.2
🌳 Code Tree / Hierarchy
H35 Other retinal disorders ❌ Non-billable
│
├── H35.3 Macular degeneration and cysts ❌ Non-billable
│ │
│ ├── H35.31 Nonexudative age-related macular degeneration ❌ Non-billable
│ └── H35.32 Exudative age-related macular degeneration ❌ Non-billable
│ │
│ ├── H35.321 Exudative age-related macular degeneration, right eye ❌ Non-billable
│ │ │
│ │ ├── [[H35.3211]] Exudative AMD, right eye, with active CNV ◀ THIS CODE ✅ Billable
│ │ ├── [[H35.3212]] Exudative AMD, right eye, with inactive CNV ✅ Billable
│ │ └── [[H35.3213]] Exudative AMD, right eye, with inactive scar ✅ Billable
│ │
│ ├── H35.322 Exudative age-related macular degeneration, left eye ❌ Non-billable
│ └── H35.323 Exudative age-related macular degeneration, bilateral ❌ Non-Billable
Specificity and Prior Authorization
Medicare and commercial MACs have strict Local Coverage Determinations (LCDs) for anti-VEGF drugs. Submitting the generic or non-billable parent code
H35.321will result in an immediate claim denial. You must code to the 7th character ([[H35.3211]]) to prove the neovascularization is active and warrants the injection.
✅ Includes
The following clinical terms and scenarios map to H35.3211 when documented for the right eye:
- Exudative ARMD with subretinal hemorrhage
- Wet AMD with active subretinal fluid (SRF) or intraretinal fluid (IRF) on OCT
- Choroidal neovascular membrane (CNVM), active, secondary to AMD
- Disciform macular degeneration, active stage
❌ Excludes
Excludes 1 — Cannot Be Coded Simultaneously with H35.3211
| Code | Description | Note |
|---|---|---|
| E11.3- | Type 2 diabetes mellitus with diabetic retinopathy | Exudative retinopathy caused by diabetes is coded to the E08-E13 series. AMD and Diabetic Retinopathy have distinct pathophysiology, though a patient can theoretically have both. If the exudation is purely diabetic, H35.3211 is excluded.1 |
| H35.5- | Hereditary macular degeneration | Conditions like Stargardt disease or Best disease are genetically distinct from age-related macular degeneration. |
Excludes 1 Violation Risk
A common error is coding both wet AMD (
[[H35.3211]]) and dry AMD ([[H35.311-]]) for the same eye. According to coding guidelines, when a patient progresses from dry to wet AMD in the same eye, only the wet AMD is coded, as it is the more severe manifestation encompassing the underlying degenerative process. You may code dry AMD for the left eye alongside wet AMD for the right eye.
Excludes 2 — May Be Coded in Addition if Separately Present
| Code | Description | Note |
|---|---|---|
| H35.81 | Retinal edema | Only code additionally if the edema is located outside the macula and unrelated to the AMD process. Macular edema is inherent to active wet AMD and is not coded separately. |
📋 Clinical Overview
CNV Activity Stage Comparison
Accurate assignment of the 7th character depends entirely on the provider’s assessment of the choroidal neovascularization (CNV) status.
| Feature | H35.3211 — Active CNV | H35.3212 — Inactive CNV | H35.3213 — Inactive Scar |
|---|---|---|---|
| Clinical Finding | Fluid, fresh hemorrhage, or progressive thickening on OCT. | Absence of subretinal fluid/blood; macula is “dry” on OCT. | Fibrovascular scar tissue formation; end-stage structural damage. |
| Treatment Status | Requires active therapy (e.g., anti-VEGF injections). | Typically in a “treat-and-extend” or observation phase. | Irreversible; no active injections administered for the scar itself. |
| Visual Prognosis | Guarded; immediate intervention needed to preserve sight. | Stable; monitoring required to catch reactivation. | Poor central vision permanently established. |
CDI Query Trigger — "Wet AMD" Without Activity Status
If the physician simply documents “Wet AMD, right eye” or “Exudative AMD OD” but orders an intravitreal injection, the coder lacks the required 7th character for activity. Query the provider: “Please clarify the status of the choroidal neovascularization (CNV) for the right eye: Active, Inactive, or Inactive Scar?”
Common Diagnoses / Clinical Indications
Relevant manifestations and common presenting symptoms associated with active wet AMD:
- Metamorphopsia: Straight lines appear wavy or distorted (often tested via Amsler grid).
- Central Scotoma: A dark or empty patch in the center of vision.
- Subretinal Hemorrhage: Bleeding underneath the retina visible on fundus exam.
Coding Manifestations
Always code documented manifestations or associated ocular findings if they impact care. Examples include:
- H53.411 — Scotoma involving central area, right eye
- H53.141 — Visual discomfort (Visual distortion), right eye
💰 HCC Risk Adjustment (CMS-HCC v28)
| Field | Detail |
|---|---|
| CMS-HCC Model Version | v28 (2024-2025 Implementation) |
| HCC Assignment | ❌ Not HCC-Mapped |
| HCC Category | N/A |
| RAF Coefficient | N/A |
H35.3211 does not map to an HCC under v28.
Capture Annually
While this specific code does not map to a payment HCC, advanced wet AMD often leads to statutory blindness or severe visual impairment. If the patient’s vision degrades to blindness, ensure codes from the
H54.-category (Blindness and low vision) are captured, as those do map to HCCs (e.g., HCC 122 - Profound Blindness).3
🏥 DRG Assignment
MDC 02 — Diseases and Disorders of the Eye
| DRG | Title | Est. Relative Weight* |
|---|---|---|
| DRG 124 | Other Disorders of the Eye with MCC | ~1.45 - 1.55 |
| DRG 125 | Other Disorders of the Eye without MCC | ~0.75 - 0.85 |
Approximate. Verify against IPPS FY2026 Final Rule tables.
Sequencing and Complications
Inpatient admissions strictly for the treatment of macular degeneration are exceptionally rare. When
[[H35.3211]]appears on an inpatient claim, it is almost always sequenced as a secondary diagnosis (a pre-existing comorbidity) while the patient is admitted for a systemic issue (e.g., heart failure or stroke). It does not act as a CC or MCC and will not shift the DRG weight.
🔗 Related ICD-10-CM Codes
Laterality and Activity Variants
| Code | Description |
|---|---|
| H35.3211 | Exudative AMD, right eye, with active CNV ← This Code |
| H35.3221 | Exudative AMD, left eye, with active CNV |
| H35.3231 | Exudative AMD, bilateral, with active CNV |
| H35.3212 | Exudative AMD, right eye, with inactive CNV |
| H35.3213 | Exudative AMD, right eye, with inactive scar |
Phenotype Variants (Dry AMD)
| Code | Description |
|---|---|
| H35.3111 | Nonexudative age-related macular degeneration, right eye, early dry stage |
| H35.3112 | Nonexudative age-related macular degeneration, right eye, intermediate dry stage |
| H35.3113 | Nonexudative age-related macular degeneration, right eye, advanced atrophic without subfoveal involvement |
🛠️ Commonly Associated CPT Codes (Outpatient and Profee Setting)
Outpatient Retina Clinic Context
Active exudative AMD is primarily managed in an outpatient retina specialist setting. Diagnostic imaging (OCT) is utilized to measure fluid, and intravitreal anti-VEGF injections are the standard of care.
| CPT/HCPCS Code | Description | Profee Coding Notes (Modifier 26/RT) |
|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | The primary surgical procedure code. Must append modifier -RT to match the right eye diagnosis. |
| 92134 | Scanning computerized ophthalmic diagnostic imaging, retina | OCT used to visualize subretinal fluid and confirm “active” status. Typically billed globally in the office. |
| 92250 | Fundus photography with interpretation and report | Used to document baseline hemorrhages or membrane changes. |
| J0178 | Injection, aflibercept, 1 mg | HCPCS code for Eylea. Units billed depend on dosage (e.g., 2 units for 2mg). |
| J2778 | Injection, ranibizumab, 0.1 mg | HCPCS code for Lucentis. |
NCCI Bundling Considerations
- CPT 92134 (OCT) billed on the same day as CPT 92250 (Fundus Photography) is bundled under NCCI edits. Medicare rarely pays for both on the same date of service unless there is a distinctly separate medical necessity documented, in which case modifier -59 may be applied to the column 2 code.
🔬 ICD-10-CM Diagnosis Crosswalk
(Note: As an ICD-10-CM note, PCS inpatient procedures are rare; below are the most common concurrent diagnoses found alongside H35.3211)
When H35.3211 is reported, coders frequently encounter these concomitant diagnoses:
- Z79.899 — Other long term (current) drug therapy (used if patient is on long-term systemic medications that might impact bleeding).
- H53.411 — Scotoma involving central area, right eye.
- I10 — Essential (primary) hypertension (Systemic hypertension can exacerbate retinal hemorrhaging).
💊 Coding Scenarios and Examples
Scenario 1 — Outpatient Retina Clinic: Active Wet AMD Treatment
Clinical Vignette: A 76-year-old male presents with worsening central vision distortion in his right eye. Dilated fundus exam reveals a new subretinal hemorrhage in the macula OD. The OCT shows active subretinal fluid and choroidal neovascular membrane formation. Left eye shows intermediate dry drusen without fluid. The physician administers an intravitreal injection of Eylea (aflibercept, 2mg) into the right eye.
CPT / HCPCS (Profee):
- 67028-RT — Intravitreal injection, right eye
- 92134 — OCT Retina, bilateral
- J0178 x 2 units — Aflibercept injection, 2mg
ICD-10-CM:
- H35.3211 — Exudative AMD, right eye, with active CNV (Supports medical necessity for injection, Eylea, and OCT)
- H35.3122 — Nonexudative AMD, left eye, intermediate dry stage
Scenario 2 — Outpatient: Treat and Extend Protocol (Inactive)
Clinical Vignette: A 72-year-old female returns for her 8-week follow-up injection for wet AMD in the right eye. Her vision is stable. The OCT shows a “dry” macula with no subretinal fluid or active leakage today. Because she is on a treat-and-extend protocol to prevent reactivation, the physician proceeds with the planned Lucentis injection OD.
CPT / HCPCS (Profee):
- 67028-RT — Intravitreal injection, right eye
- J2778 x 5 units — Ranibizumab injection, 0.5mg
ICD-10-CM:
- H35.3212 — Exudative AMD, right eye, with inactive CNV (Because the macula is dry today, the activity status is inactive, even though the injection is given prophylactically)
MS-DRG Assignment: N/A (Outpatient). Note that submitting [[H35.3211]] (Active) here would be factually incorrect based on the “dry macula” documentation.
Scenario 3 — CDI Query: Incomplete Laterality and Activity
Clinical Vignette: The clinic note reads: “Patient here for monthly wet macular degeneration follow up. Subretinal fluid remains present. Will inject Avastin.” Neither the eye laterality nor the CNV status is explicitly documented in the assessment, though the fluid indicates active disease.
Action / Outcome: The coder cannot assume laterality based on previous notes without current confirmation, nor can they assume the 7th character activity status based solely on the word “fluid.”
Query Response: The provider amends the note: “Wet macular degeneration, right eye. The presence of subretinal fluid confirms active choroidal neovascularization.”
Corrected ICD-10-CM Coding:
- H35.3211 — Exudative AMD, right eye, with active CNV
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | |
|---|---|
| ❌ | Using “Active” for Maintenance Injections on a Dry Retina. A common error is defaulting to H35.3211 (Active) for every injection visit. If the provider notes the macula is “dry,” “fluid-free,” or “stable” without leakage, the CNV is inactive, and the code should be H35.3212, even if an anti-VEGF injection is administered to keep it inactive.4 |
| ❌ | Defaulting to Unspecified Eye (H35.3291). Using the 6th character “9” (unspecified eye) will almost universally trigger a medical necessity denial for surgical procedures (like CPT 67028) that require laterality modifiers (-RT/-LT). |
| ✅ | Check the Contralateral Eye. AMD is often bilateral but asymmetrical. A patient may have active wet AMD in the right eye (H35.3211) and intermediate dry AMD in the left eye (H35.3122). Always code the status of both eyes if evaluated. |
| ✅ | Link the Drug to the Diagnosis. Ensure that HCPCS J-codes (J0178, J2778, J9035) are explicitly pointed to the H35.3211 diagnosis on the CMS-1500 claim form. Failure to link the drug to the active CNV diagnosis will result in costly payer rejections. |
| ✅ | Watch NCCI Edits on Imaging. If the provider bills CPT 92134 (OCT) and CPT 92250 (Fundus Photos) on the same day, they are bundled. Do not use modifier -59 unless the photo was taken for a completely different diagnosis (e.g., a nevus) in a different part of the eye. |
📚 Sources
1. CMS/NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2026. 2. American Academy of Ophthalmology (AAO). Age-Related Macular Degeneration Preferred Practice Pattern. 3. CMS. 2025-2026 Medicare Advantage Risk Adjustment — CMS-HCC Model v28 ICD-10-CM Mappings. 4. American Academy of Ophthalmic Executives (AAOE). Coding for Treat-and-Extend AMD Protocols. (Review of 7th character selection for active vs. inactive CNV). 5. AMA. CPT Professional Edition 2026. Surgery / Eye and Ocular Adnexa.